NCT00291421

Brief Summary

The purpose of this study is to collect and compare information regarding the treatment and outcome of patients diagnosed with Alzheimer's disease who are receiving either drug or nondrug treatment. Information will be collected from patients and their primary caregivers.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,360

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2002

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2002

Completed
3.6 years until next milestone

First Submitted

Initial submission to the registry

February 10, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 14, 2006

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2006

Completed
Last Updated

April 16, 2013

Status Verified

April 1, 2013

First QC Date

February 10, 2006

Last Update Submit

April 15, 2013

Conditions

Alzheimer DiseaseDementiaNervous System DiseasesMental DisordersBrain Diseases

Keywords

Alzheimer's DiseaseDementiaBrain DiseaseMemory LossCaregiverPrimary CaregiverObservationgalantaminedonepezilrivastigmineQuality of life

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with new or previous mild or moderate Alzheimer's disease diagnosed by a doctor according to medically-accepted definitions
  • Patients living in ordinary households (for example in their own home or in the home of a family member or friend, not in nursing homes or other long-term care facilities)

You may not qualify if:

  • Patients who are currently participating in another clinical trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Alzheimer DiseaseDementiaNervous System DiseasesMental DisordersBrain DiseasesMemory Disorders

Condition Hierarchy (Ancestors)

Central Nervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersNeurobehavioral ManifestationsNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Janssen Pharmaceutica N.V. Clinical Trial

    Janssen Pharmaceutica N.V.

    STUDY DIRECTOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

February 10, 2006

First Posted

February 14, 2006

Study Start

July 1, 2002

Study Completion

May 1, 2006

Last Updated

April 16, 2013

Record last verified: 2013-04